Evidence map›Paper›PMID 39418259›Full record

ArticlePloS one2024

Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry.

Olawale Amubieya, Jamie L Todd, Megan L Neely, Robert J Kaner, Joseph A Lasky, Andrew Namen, Christian Hesslinger, Scott M Palmer, S Samuel Weigt, John A Belperio

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Olawale AmubieyaDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.ORCID 0000-0002-4645-1558
Jamie L ToddDuke Clinical Research Institute, Durham, North Carolina, United States of America.
Megan L NeelyDuke Clinical Research Institute, Durham, North Carolina, United States of America.
Robert J KanerDepartments of Medicine and Genetic Medicine, Weill Cornell Medicine, New York, New York, United States of America.
Joseph A LaskySchool of Medicine, Tulane University, New Orleans, Louisiana, United States of America.
Andrew NamenDepartment of Internal Medicine, Section of Pulmonary, Critical Care and Allergy and Immunologic Diseases, Atrium Health Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.
Christian HesslingerTranslational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Scott M PalmerDuke Clinical Research Institute, Durham, North Carolina, United States of America.
S Samuel WeigtDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.ORCID 0000-0001-5351-8936
John A BelperioDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.ORCID 0000-0003-2379-5486

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe assessed the prognostic utility of circulating levels of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in patients with idiopathic pulmonary fibrosis (IPF) in the IPF-PRO Registry.

methodsMMP and TIMP concentrations were quantified by ELISA in plasma from 300 patients. A Cox proportional hazard regression model was used to assess associations between select MMPs and TIMPs and death and disease progression (absolute decline in forced vital capacity ≥10% predicted, death, or lung transplant).

resultsOver a median follow-up of 30.4 months, 98 patients died and 182 patients had disease progression. In unadjusted analyses, higher concentrations of MMPs 2, 3, 8 and 9 and TIMPs 1, 2 and 4 were associated with an increased risk of death. MMPs 2 and 8 and TIMP1 remained associated with death after adjustment for clinical factors. In unadjusted analyses, higher concentrations of MMPs 8 and 9 and TIMPs 1 and 4 were associated with an increased risk of disease progression. MMPs 8 and 9 and TIMP1 remained associated with progression after adjustment for clinical factors.

conclusionCirculating levels of MMP8 and TIMP1 may provide information on the risk of outcomes in patients with IPF not captured by clinical measures.

Indexed as

Disease ProgressionIdiopathic Pulmonary FibrosisMatrix MetalloproteinasesRegistriesTissue Inhibitor of MetalloproteinasesAgedBiomarkersFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsTissue Inhibitor of Metalloproteinase-1BiomarkersMatrix MetalloproteinasesTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinases

Identifiers

PMID39418259
PMCPMC11486396

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.